+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Influenza Diagnostics Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805777
The global influenza diagnostic market value was USD 780.6 million in 2022, driven by the increasing
burden of influenza and the need for rapid and accurate diagnosis across the globe. The market size is anticipated to grow at a CAGR of 9% during the forecast period of 2023-2031 to achieve a value of USD 1,695.3 million by 2031.

Influenza Diagnostic: Introduction

Influenza, commonly known as the flu, is a highly contagious respiratory illness caused by influenza viruses. Rapid and accurate diagnosis of influenza is crucial for effective management and control of the disease. Influenza diagnostic tests are designed to identify the presence of the influenza virus in respiratory specimens, aiding in early detection, proper treatment, and prevention of the spread of the virus.

Key Trends in the Influenza Diagnostic Market

Some key trends involved in the influenza diagnostic market are as follows:
  • Growing Demand for Point-of-Care Testing: There is an increasing trend towards point-of-care testing for influenza, which allows for rapid and convenient diagnosis at the patient's location. Point-of-care tests provide quick results, enabling healthcare providers to make timely treatment decisions and take appropriate infection control measures. The demand for user-friendly, portable, and reliable point-of-care testing devices is on the rise
  • Technological Advancements: The field of influenza diagnostics is witnessing technological advancements that enhance the accuracy, sensitivity, and speed of diagnostic tests. Molecular diagnostic techniques such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS) are becoming more widely used, offering improved sensitivity and the ability to detect multiple strains of the influenza virus. Additionally, the development of rapid diagnostic tests utilizing advanced immunochromatographic and immunoassay techniques is contributing to faster and more efficient diagnosis
  • Shift towards Multiplex Testing: Multiplex testing, which allows for the simultaneous detection of multiple respiratory pathogens including influenza, is gaining prominence in the influenza diagnostic market. This approach offers the advantage of identifying co-infections and differentiating between different respiratory viruses, enabling more targeted and accurate treatment decisions. Multiplex testing can help in reducing healthcare costs, optimizing antimicrobial usage, and improving patient outcomes

Influenza Diagnostic Market Segmentations

Market Breakup by Test Type

Traditional Diagnostic Test

  • Rapid Influenza Diagnostic Test (RIDT)
  • Viral Culture
  • Direct Fluorescent Antibody (DFA) Test
  • Serological Assay

Molecular Diagnostic Assay

  • Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
  • Nucleic Acid Sequence-Based Amplification (NASBA) Test
  • Loop-Mediated Isothermal Amplification-Based Assay (LAMP)
  • Simple Amplification-Based Assay (SAMBA)
  • Others

Market by Product

  • Test Kits
  • Instruments

Market by End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Laboratory
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Influenza Diagnostic Market Scenario

The global influenza diagnostic market plays a critical role in the early detection and management of influenza outbreaks. Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. Rapid and accurate diagnosis is crucial to initiate timely treatment, implement appropriate infection control measures, and prevent the spread of the virus.

The market for influenza diagnostics encompasses a wide range of products and technologies, including rapid antigen tests, molecular tests, and immunoassays. These diagnostic tools are used in various healthcare settings such as hospitals, clinics, laboratories, and point-of-care facilities.

The market is driven by several factors, including the global burden of influenza, increasing awareness about the importance of early diagnosis, and the development of advanced diagnostic technologies. Additionally, government initiatives and programs aimed at influenza surveillance and control are also contributing to the market growth.

In conclusion, the global influenza diagnostic market is experiencing steady growth due to the increasing burden of influenza and the need for rapid and accurate diagnosis. Advancements in diagnostic technologies, government initiatives, and growing awareness are driving market expansion. As the global healthcare sector continues to prioritize the prevention and control of infectious diseases, the demand for effective influenza diagnostic tools is expected to rise, presenting opportunities for market players to develop innovative solutions and contribute to the fight against influenza outbreaks.

Influenza Diagnostic Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience Inc
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc
  • Hologic, Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Influenza Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Influenza Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Influenza Epidemiology (2016-2031)
5.3 Europe Influenza Epidemiology (2016-2031)
5.4 Asia Pacific Influenza Epidemiology (2016-2031)
5.5 Latin America Influenza Epidemiology (2016-2031)
5.6 Middle East and Africa Influenza Epidemiology (2016-2031)
6 Global Influenza Diagnostic Market Overview
6.1 Global Influenza Diagnostic Market Historical Value (2016-2022)
6.2 Global Influenza Diagnostic Market Forecast Value (2023-2031)
7 Global Influenza Diagnostic Market Landscape
7.1 Influenza Diagnostic: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Influenza Diagnostic: Product Landscape
7.2.1 Analysis by Test Type
7.2.2 Analysis by Product
7.2.3 Analysis by End User
8 Influenza Diagnostic Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Influenza Diagnostic Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Influenza Diagnostic Market Segmentation
11.1 Global Influenza Diagnostic Market by Test Type
11.1.1 Market Overview
11.1.2 Traditional Diagnostic Test Rapid Influenza Diagnostic Test (RIDT) Viral Culture Direct Fluorescent Antibody (DFA) Test Serological Assay
11.1.3 Molecular Diagnostic Assay Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Nucleic Acid Sequence-Based Amplification (NASBA) Test Loop-Mediated Isothermal Amplification-Based Assay (LAMP) Simple Amplification-Based Assay (SAMBA) Others
11.2 Global Influenza Diagnostic Market by Product
11.2.1 Market Overview
11.2.2 Test Kits
11.2.3 Instruments
11.3 Global Influenza Diagnostic Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Diagnostic Laboratories
11.3.4 Research Laboratory
11.3.5 Others
11.4 Global Influenza Diagnostic Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Influenza Diagnostic Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Influenza Diagnostic Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Influenza Diagnostic Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Influenza Diagnostic Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Influenza Diagnostic Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Abbott Laboratories
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Becton, Dickinson and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Coris BioConcept
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 DiaSorin SpA
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Luminex Corporation
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Meridian Bioscience Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Quidel Corporation
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Sekisui Diagnostics
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Thermo Fisher Scientific Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Hologic, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Influenza Diagnostic - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Abbott Laboratories
  • Becton
  • Dickinson and Company
  • Coris BioConcept
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Luminex Corporation
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.



Table Information